No difference in watch, remove or radiate approach to prostate cancer

A large 10-year UK study of men with localised prostate cancer has shown no significant difference between active monitoring, radical prostatectomy and radical radiotherapy – but the active interventions were associated with more side-effects. 
In the study carried out between 2001 and 2009, 82 429 men …

More details...

Radiotherapy delay possibly OK in prostate cancer

For men with prostate cancer, initiation of radiotherapy (RT) up to six months after androgen deprivation therapy (ADT) is not associated with worse overall survival, according to a research letter published JAMA Oncology.
The researchers found that among men with unfavourable intermediate-risk cancer, the 10-year overall …

More details...

New drug offers hope in osteoarthritis

A retrospective analysis of a large osteoarthritis (OA) trial has shown that the interleukin-1beta (IL-1β) inhibitor, canakinumab, can significantly reduce the need for total hip/knee replacement (THR/TKR).
The study, published in Annals of Internal Medicine, involved 10 061 participants receiving placebo or canakinumab (50, 150, or …

More details...

Barber shops and male mental health

Barber shops may provide a vital opportunity to start engaging men in discussing their mental health, according to a recent initiative led by Cardiff and Vale University Health Board and the Lions Barber Collective, in collaboration with Cardiff and Vale College and Truth N Hair.
Currently, …

More details...

Little evidence for drugs in prostatitis

There is very little evidence of benefit for pharmacological interventions in the management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), according to a Cochrane meta-analysis.
The analysis included 99 unique studies of 16 treatments in 9119 men with CP/CPPS.
The authors found low‐ to very low‐quality evidence …

More details...

New drug promising in CKD

A phase 3 study has shown that finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, can reduce the risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes.
According to manufacturer Bayer, finerenone added to standard therapy reduced the combined risk of time to …

More details...

Active surveillance a safe option in low-risk prostate cancer

Active surveillance of patients with low-risk (Grade 1) prostate cancer can keep patients treatment-free for many years, according to a new US study published in The Journal of Urology. 
In a retrospective evaluation of a large active surveillance cohort, the authors reported a treatment-free survival at …

More details...

Call for COVID-19 men to donate plasma

The NHS Blood and Transplant Service is calling for men who have recovered from COVID-19 infection to donate plasma for use in clinical trials.
Men are needed because their plasma is particularly rich in antibodies. Of donations received so far from men, 43% had high enough …

More details...

Prostate cancer most commonly diagnosed cancer 

Prostate cancer has become the UK’s most commonly diagnosed cancer for the first time, according to Prostate Cancer UK (PCUK).
Prostate cancer has overtaken breast, lung and bowel cancer to become the most commonly diagnosed overall with 57 192 diagnoses according to latest annual figures. Prostate cancer diagnoses have more than doubled over the …

More details...

Men’s health absent from policy agendas

Men’s health is generally absent from policies and programmes at all levels, according to a new report from the Global Action on Men’s Health.
From the Margins to the Mainstream takes an in-depth look at the role of policy in men’s health. As well as identifying …

More details...

Web design and marketing agency Leamington Spa